Literature DB >> 2983100

Role of antibody in primary and recurrent herpes simplex virus infection.

A Simmons, A A Nash.   

Abstract

When herpes simplex virus was inoculated into the flank of a BALB/c mouse by scarification, the local replication of virus was followed by the establishment of an acute ganglionic infection. The subsequent centrifugal spread of this virus along nerves to the skin of the whole dermatome led to the development of a bandlike "zosteriform" rash. This represents a highly reproducible system in which virus travels through the nervous system synchronously in large numbers of animals. The transection of peripheral nerves at various times after infection showed that the virus had completed the round trip 60 h after inoculation into the upper flank and was detectable as infectious virus by 74 h postinfection. After the administration of virus, neutralizing but not nonneutralizing antibodies prevented the development of the zosteriform rash. The target epitopes of the protective antibodies were not confined to a single glycoprotein. Neutralizing antibody was effective even when given up to 60 h postinfection and was protective even when administered after sensory neurotomy at this time. Antibody was therefore able to prevent clinically and virologically detectable infection of the skin, presumably by acting peripherally on virus emerging from nerve endings. A quantitative estimate of the action of one of the neutralizing monoclonal antibody preparations, AP7, showed that high titers (several times higher than those normally found in immune mice) were needed to prevent this type of infection. These results are discussed in relation to antibody prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983100      PMCID: PMC254730     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.

Authors:  R R McKendall; T Klassen; J R Baringer
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

2.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

3.  Antibody-dependent cellular protection against herpes simplex virus dissemination as revealed by viral plauqe and infectivity assays.

Authors:  F Shimizu; K Hanaumi; Y Shimizu; K Kumagai
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

4.  Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection.

Authors:  J J Hooks; W Burns; K Hayashi; S Geis; A L Notkins
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

5.  Postexposure serum prophylaxis of neonatal herpes simplex virus infection of mice.

Authors:  S Baron; M G Worthington; J Williams; J W Gaines
Journal:  Nature       Date:  1976-06-10       Impact factor: 49.962

6.  Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus.

Authors:  S L Shore; A J Nahmias; S E Starr; P A Wood; D E McFarlin
Journal:  Nature       Date:  1974-09-27       Impact factor: 49.962

7.  A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans.

Authors:  R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

8.  Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.

Authors:  T J Hill; H J Field; W A Blyth
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

9.  The natural history of recurrent herpes simplex labialis: implications for antiviral therapy.

Authors:  S L Spruance; J C Overall; E R Kern; G G Krueger; V Pliam; W Miller
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

10.  Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice.

Authors:  H J Field; S E Bell; G B Elion; A A Nash; P Wildy
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

View more
  36 in total

1.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

2.  Glycoprotein gI of pseudorabies virus promotes cell fusion and virus spread via direct cell-to-cell transmission.

Authors:  L Zsak; F Zuckermann; N Sugg; T Ben-Porat
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Eradication of herpes simplex virus persistence in rat trigeminal ganglia by retrograde axoplasmic transport.

Authors:  Y Iwasaki; T Yamamoto; H Konno; H Iizuka; H Kudo
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  Replication of herpes simplex virus type 1 within trigeminal ganglia is required for high frequency but not high viral genome copy number latency.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Structural properties and reactivity of N-terminal synthetic peptides of herpes simplex virus type 1 glycoprotein D by using antipeptide antibodies and group VII monoclonal antibodies.

Authors:  D L Bosch; H J Geerligs; W J Weijer; M Feijlbrief; G W Welling; S Welling-Wester
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

7.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2.

Authors:  Gregg N Milligan; Michael G Meador; Chin-Fun Chu; Christal G Young; Talitha L Martin; Nigel Bourne
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  T Nagashunmugam; J Lubinski; L Wang; L T Goldstein; B S Weeks; P Sundaresan; E H Kang; G Dubin; H M Friedman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro.

Authors:  R Burioni; R A Williamson; P P Sanna; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.